Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - STOCKHEAD.COM.AU - A La Une - 10/Sep 23:38
Dimerix first patient completes Phase 3 trial and enters into long-term DMX-200 Open Label Extension study
Dimerix has enrolled the first patient into the Open Label Extension study for its kidney disease drug candidate DMX-200 after ...
Articles similaires
Key paediatric milestone reached in Dimerix’s kidney-disease drug trial
stockhead.com.au - 12/Sep 03:41
Clinical-stage biotech Dimerix has achieved a key milestone with the first paediatric site opening for its ACTION3 Phase 3 clinical ...
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
stockhead.com.au - 04/Sep 20:45
Despite many obstacles, Dimerix is getting to the pointy end of things with its kidney drug trial program. ...
Bio Curious: How Dimerix negotiates the ‘valleys of death’ on the winding road to drug approval
stockhead.com.au - 04/Sep 20:45
Despite many obstacles, Dimerix is getting to the pointy end of things with its kidney drug trial program. ...
First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML
drugs.com - 06/Sep 07:09
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
stockhead.com.au - 09/Sep 04:15
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
stockhead.com.au - 09/Sep 04:15
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
KalVista Presents Sebetralstat Data at Bradykinin Symposium 2024
haei.org - 06/Sep 18:54
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...
First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
drugs.com - 05/Sep 04:09
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
zacks.com - 09/Sep 15:58
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and...
Les derniers communiqués
-
Aucun élément